The US Food and Drug Administration Provides Notice of 510(k) Clearance of GammaTile Therapy in the Treatment of Recurrent Intracranial Neoplasms
T Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for GammaTile® Therapy. Patients with newly diagnosed malignant brain tumors are now eligible to receive the FDA-cleared surgically targeted radiation therapy (STaRT).